Usefulness of Cone-Beam CT-Based Liver Perfusion Mapping for Evaluating the Response of Hepatocellular Carcinoma to Conventional Transarterial Chemoembolization

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Mar 6

PMID 33670213

Citations 2

Authors

Sun Young Choi

Kyung Ah Kim

Woosun Choi

Yohan Kwon

Soo Buem Cho

Affiliations

Soon will be listed here.

Abstract

We investigated the cone beam computed tomography (CBCT)-based-liver-perfusion-mapping usefulness during transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) to access treatment response and predict outcomes. From October 2016 to September 2018, 42 patients with HCCs scheduled for conventional TACE were prospectively enrolled. Three reviewers evaluated the unenhanced and contrast-enhanced CBCT and CBCT-based-liver-perfusion-mapping of each tumor. Parenchymal blood volume (PBV) was measured. The operator's judgment on the technical results was recorded. Response outcome was determined on follow-up CT or magnetic resonance imaging, according to the modified Response Evaluation Criteria in Solid Tumors. Diagnostic performance for detection of a viable tumor was evaluated using multiple logistic regression with C-statistics. CBCT-based-liver-perfusion-mapping and the maximum PBV of the tumor were significant in multiple logistic regression analysis of response ( < 0.0001, = 0.0448, respectively), with C-statistics of 0.9540 and 0.7484, respectively. Diagnostic accuracy of operator's judgment was 79.66% (95%CI 69.39%-89.93%). Diagnostic performance of CBCT-based-liver-perfusion-mapping showed a high concordance in three reviewers. The mean PBV of tumor, maximum PBV of tumor, and mean PBV of liver significantly decreased after TACE (each < 0.001). In ROC curve analysis, the AUC for prediction of residual tumor by the maximum PBV of tumor after TACE was 0.7523, with 80.8% sensitivity and 60.6% specificity.

Citing Articles

Precision Imaging Guidance in the Era of Precision Oncology: An Update of Imaging Tools for Interventional Procedures.

Floridi C, Cellina M, Irmici G, Bruno A, Rossini N, Borgheresi A J Clin Med. 2022; 11(14).

PMID: 35887791 PMC: 9322069. DOI: 10.3390/jcm11144028.

In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?.

Bucalau A, Tancredi I, Verset G Cancers (Basel). 2021; 13(20).

PMID: 34680278 PMC: 8533902. DOI: 10.3390/cancers13205129.

References

Gaba R, Lewandowski R, Hickey R, Baerlocher M, Cohen E, Dariushnia S . Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol. 2016; 27(4):457-73. DOI: 10.1016/j.jvir.2015.12.752. View

Georgiades C, Geschwind J, Harrison N, Hines-Peralta A, Liapi E, Hong K . Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?. Radiology. 2012; 265(1):115-23. PMC: 4137783. DOI: 10.1148/radiol.12112264. View

Niu K, Yang P, Wu Y, Struffert T, Doerfler A, Schafer S . C-Arm Conebeam CT Perfusion Imaging in the Angiographic Suite: A Comparison with Multidetector CT Perfusion Imaging. AJNR Am J Neuroradiol. 2016; 37(7):1303-9. PMC: 4946984. DOI: 10.3174/ajnr.A4691. View

Kim B, Kim S, Kim K, Chung Y, Kim M, Park M . Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015; 62(6):1304-10. DOI: 10.1016/j.jhep.2015.01.022. View

Kim S, Kamaya A, Willmann J . CT perfusion of the liver: principles and applications in oncology. Radiology. 2014; 272(2):322-44. PMC: 4263626. DOI: 10.1148/radiol.14130091. View

Bley T, Strother C, Pulfer K, Royalty K, Zellerhoff M, Deuerling-Zheng Y . C-arm CT measurement of cerebral blood volume in ischemic stroke: an experimental study in canines. AJNR Am J Neuroradiol. 2010; 31(3):536-40. PMC: 7963973. DOI: 10.3174/ajnr.A1851. View

Takayasu K, Arii S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K . Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 2000; 175(3):699-704. DOI: 10.2214/ajr.175.3.1750699. View

Miles K . Perfusion CT for the assessment of tumour vascularity: which protocol?. Br J Radiol. 2004; 76 Spec No 1:S36-42. DOI: 10.1259/bjr/18486642. View

Sieghart W, Hucke F, Peck-Radosavljevic M . Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015; 62(5):1187-95. DOI: 10.1016/j.jhep.2015.02.010. View

10.

Landis J, Koch G . The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1):159-74. View

11.

Fischer M, Kartalis N, Grigoriadis A, Loizou L, Stal P, Leidner B . Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. Eur Radiol. 2015; 25(11):3123-32. DOI: 10.1007/s00330-015-3732-1. View

12.

Datta S, Muller K, Moore T, Molvin L, Gehrisch S, Rosenberg J . Dynamic Measurement of Arterial Liver Perfusion With an Interventional C-Arm System. Invest Radiol. 2017; 52(8):456-461. DOI: 10.1097/RLI.0000000000000368. View

13.

Kim K, Choi S, Kim M, Baek S, Park S, Yoo K . The Efficacy of Cone-Beam CT-Based Liver Perfusion Mapping to Predict Initial Response of Hepatocellular Carcinoma to Transarterial Chemoembolization. J Vasc Interv Radiol. 2019; 30(3):358-369. DOI: 10.1016/j.jvir.2018.10.002. View

14.

Chiu R, Yap W, Patel R, Liu D, Klass D, Harris A . Hepatocellular Carcinoma Post Embolotherapy: Imaging Appearances and Pitfalls on Computed Tomography and Magnetic Resonance Imaging. Can Assoc Radiol J. 2016; 67(2):158-72. DOI: 10.1016/j.carj.2015.09.006. View

15.

Loffroy R, Lin M, Yenokyan G, Rao P, Bhagat N, Noordhoek N . Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?. Radiology. 2012; 266(2):636-48. PMC: 3558876. DOI: 10.1148/radiol.12112316. View

16.

Miles K . Functional computed tomography in oncology. Eur J Cancer. 2002; 38(16):2079-84. DOI: 10.1016/s0959-8049(02)00386-6. View

17.

. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View

18.

Jung E, Kim J, Yoon E, Lee H, Lee S, Suh S . Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013; 58(6):1181-7. DOI: 10.1016/j.jhep.2013.01.039. View

19.

Syha R, Grozinger G, Grosse U, Maurer M, Zender L, Horger M . Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma. Invest Radiol. 2015; 51(2):121-6. DOI: 10.1097/RLI.0000000000000215. View

20.

Spira D, Schulze M, Sauter A, Brodoefel H, Brechtel K, Claussen C . Volume perfusion-CT of the liver: insights and applications. Eur J Radiol. 2011; 81(7):1471-8. DOI: 10.1016/j.ejrad.2011.04.010. View